Athersys is developing off-the-shelf multipotent adult progenitor cells (MAPCs) to treat a variety of indications, with ischemic stroke, acute myocardial infarction (AMI) and acute respiratory distress syndrome (ARDS) the most advanced. The recent Phase II data in stroke indicated strong trends in favor of MultiStem across multiple endpoints, though the study did miss the primary endpoint on an intent-to-treat basis. Clinical trial design changes in future trials should help increase the prog
14 Dec 2015
MultiStem signal in stroke
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
MultiStem signal in stroke
Athersys is developing off-the-shelf multipotent adult progenitor cells (MAPCs) to treat a variety of indications, with ischemic stroke, acute myocardial infarction (AMI) and acute respiratory distress syndrome (ARDS) the most advanced. The recent Phase II data in stroke indicated strong trends in favor of MultiStem across multiple endpoints, though the study did miss the primary endpoint on an intent-to-treat basis. Clinical trial design changes in future trials should help increase the prog